Kyverna Therapeutics, Inc.KYTXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P9
Near historical low
vs 2Y Ago
-0.5x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -16.12% |
| Q2 2025 | -4.32% |
| Q1 2025 | 13.71% |
| Q4 2024 | 12.77% |
| Q3 2024 | 6.85% |
| Q2 2024 | 121456.33% |
| Q1 2024 | -99.87% |
| Q4 2023 | 25.79% |
| Q3 2023 | 31.13% |
| Q2 2023 | 19.45% |
| Q1 2023 | 30.15% |
| Q4 2022 | 0.00% |